A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

Inclusion Criteria:

• Completion of last visit (or early termination visit, if applicable) for Study Q2788g
• Signed Informed Consent Form
• Use of an effective method of contraception for females of childbearing potential
• Body weight ≥ 20 kg and ≤ 150 kg
• IgE level ≤ 1300 IU/mL (Note: Subjects with an IgE < 30 IU/mL will be dosed at the lowest level on the dosing table [30 IU/mL], thus enabling better understanding of the role of Xolair in peanut allergic subjects who have low total IgE levels.)

Exclusion Criteria:

• Withdrawal from Study Q2788g prior to study closure or the final study visit (Week 36)
• Current participation in another investigational study
• Pregnancy or lactation
• History of brittle asthma
• Aspirin-sensitive asthma
• Known hypersensitivity to any ingredients of Xolair, including its excipients (sucrose, histidine, polysorbate 20)
• Have a polymorrphonuclear count <1500/uL
• Use of anti-coagulants, such as warfarin (Coumadin(R)), thrombolytic enzymes, or ticlopidine
• Current diagnosis of cancer, current investigation for possible cancer, or history of cancer (not including non-melanoma skin cancer)
• Thrombocytopenia as evidenced by a platelet count < 100,000/uL
• Any systemic condition requiring regular administration of an immunoglobulin